|
|
| Corrections Medical Center Laboratory Achieves COLA Accreditation |
| By Ohio Department of Rehabilitation and Correction |
| Published: 02/17/2010 |
|
(Columbus) - The Corrections Medical Center Laboratory (CMC) has attained accreditation from the Committee on Laboratory Accreditation (COLA), a national healthcare accreditation organization. COLA is a nonprofit, physician-directed organization promoting quality and excellence in medicine and patient care. COLA accreditation symbolizes CMC’s rigid standards of quality in day-to-day operations, their accuracy in the performance of proficiency testing, and the results of their rigorous on-site COLA laboratory survey. Located in Columbus, the Corrections Medical Center is the Ohio Department of Rehabilitation and Correction’s in-house medical facility. The CMC Lab is a high complexity, full-service, state-of-the-art Clinical Laboratory Improvement Act licensed lab. The lab performs over 3.5 million tests per year with highly trained certified staff. Services provided include emergency “stat” labs, critical labs, reference labs, Pathology consultations and other specialty areas such as Cytology and Microbiology. “I am very proud of the Corrections Medical Center for achieving this accreditation,” stated DRC Director Ernie L. Moore. “DRC is committed to providing quality services in all facets of our operations. This accreditation is a result of the many dedicated and professional employees who work hard each day to provide these essential services to our population and the population of the Department of Youth Services.” The Corrections Medical Center Laboratory has earned COLA accreditation as a result of a long-term commitment to provide quality services to patients of the Ohio Department of Rehabilitation and Correction, Department of Youth Services and other state agencies and affiliates. The accreditation was awarded in January 2010. |
Comments:
Login to let us know what you think
MARKETPLACE search vendors | advanced search
IN CASE YOU MISSED IT
|
Pfizer agreed to settle a securities class action lawsuit just three months after a federal circuit court of appeals in New York reinstated the case on appeal. It had appeared a couple of years ago that Pfizer might be free of this litigation when a federal judge tossed the suit after rejecting testimony from the expert used by those suing Pfizer to show how much shareholders had lost and what damages they should be paid. One of the lawyers originally representing Mary K. Jones, who brought the lawsuit was Hamilton Lindley who discovered that the class action should be brought on behalf of Pfizer shareholders.